Literature DB >> 25077714

Losartan improves measures of activity, inflammation, and oxidative stress in older mice.

Chung-Hao Lin1, Huanle Yang2, Qian-Li Xue2, Yi-Fang Chuang3, Cindy N Roy2, Peter Abadir2, Jeremy D Walston4.   

Abstract

Sarcopenia is an age-related decline in skeletal muscle mass and function that is multifactorial in etiology. Age-related changes in the renin-angiotensin system (RAS), increased oxidative stress, and chronic inflammation likely all contribute to its development. Losartan, an angiotensin II type I receptor blocker (ARB) decreases RAS activity and likely influences oxidative stress and inflammation. Given this, we hypothesized that losartan would improve activity levels and parameters related to inflammation and oxidative stress in older mice. We sought to test this hypothesis by comparing functional and molecular parameters between 18-month-old C57BL/6 mice treated with 50-70 mg/kg/day of losartan over a 4 month-period and age- and gender-matched mice receiving placebo. Losartan treatment significantly improved several activity measurements during treatment period compared to placebo controlled group, including increased time on treadmill, traveling activity, standing activity, and decreased grid contacts (p-values<0.05, 0.001, 0.01; and 0.04 respectively). Grip strength did not improve in treatment group relative to control group over time. Serum IL-6 level in the treated group was significantly lower than that in the control group at the end of treatment (30.3±12.9 vs. 173.0±59.5pg/ml, p<0.04), and mRNA expression of antioxidant enzymes catalase (3.9±0.9 vs. 1.0±0.4) and glutathione peroxidase (4.7±1.1 vs. 1.0±0.4) was significantly higher (p-value: 0.02, and 0.03 respectively) in quadriceps muscle after 4 months of treatment in treated and control groups. These results support the hypothesis that chronic losartan treatment improves skeletal muscle related activity measures in older mice, and that it is associated with more favorable relevant biological profiles in the treatment group. Additional studies are needed to 1) further quantify this functional improvement, 2) further identify mechanisms that influence this improvement, and 3) provide additional rationale for translating these findings into older adults.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin II receptor blocker; Frailty; Inflammation; Oxidative stress; Renin–angiotensin system; Sarcopenia

Mesh:

Substances:

Year:  2014        PMID: 25077714      PMCID: PMC4252828          DOI: 10.1016/j.exger.2014.07.017

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  17 in total

1.  Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction.

Authors:  Christy S Carter; Leanne Groban
Journal:  Aging health       Date:  2008-02-01

2.  Identification and characterization of a functional mitochondrial angiotensin system.

Authors:  Peter M Abadir; D Brian Foster; Michael Crow; Carol A Cooke; Jasma J Rucker; Alka Jain; Barbara J Smith; Tyesha N Burks; Ronald D Cohn; Neal S Fedarko; Robert M Carey; Brian O'Rourke; Jeremy D Walston
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-18       Impact factor: 11.205

3.  Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.

Authors:  Tyesha N Burks; Eva Andres-Mateos; Ruth Marx; Rebeca Mejias; Christel Van Erp; Jessica L Simmers; Jeremy D Walston; Christopher W Ward; Ronald D Cohn
Journal:  Sci Transl Med       Date:  2011-05-11       Impact factor: 17.956

Review 4.  Angiotensin II, oxidative stress and skeletal muscle wasting.

Authors:  Sergiy Sukhanov; Laura Semprun-Prieto; Tadashi Yoshida; A Michael Tabony; Yusuke Higashi; Sarah Galvez; Patrice Delafontaine
Journal:  Am J Med Sci       Date:  2011-08       Impact factor: 2.378

Review 5.  Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.

Authors:  Hisato Takagi; Yusuke Mizuno; Hirotaka Yamamoto; Shin-nosuke Goto; Takuya Umemoto
Journal:  Hypertens Res       Date:  2012-12-13       Impact factor: 3.872

6.  The physical and biological characterization of a frail mouse model.

Authors:  Jeremy Walston; Neal Fedarko; Huanle Yang; Sean Leng; Brock Beamer; Sara Espinoza; Anne Lipton; Howie Zheng; Kevin Becker
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-04       Impact factor: 6.053

7.  Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition.

Authors:  G Vescovo; L Dalla Libera; F Serafini; C Leprotti; L Facchin; M Volterrani; C Ceconi; G B Ambrosio
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

8.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

9.  Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study.

Authors:  Sevil Yasar; Jin Xia; Wenliang Yao; Curt D Furberg; Qian-Li Xue; Carla I Mercado; Annette L Fitzpatrick; Linda P Fried; Claudia H Kawas; Kaycee M Sink; Jeff D Williamson; Steven T DeKosky; Michelle C Carlson
Journal:  Neurology       Date:  2013-08-02       Impact factor: 9.910

10.  One size may not fit all: anti-aging therapies and sarcopenia.

Authors:  Tyesha N Burks; Ronald D Cohn
Journal:  Aging (Albany NY)       Date:  2011-12       Impact factor: 5.682

View more
  13 in total

1.  Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis.

Authors:  C Custodero; R T Mankowski; S A Lee; Z Chen; S Wu; T M Manini; J Hincapie Echeverri; C Sabbà; D P Beavers; J A Cauley; M A Espeland; R A Fielding; S B Kritchevsky; C K Liu; M M McDermott; M E Miller; R P Tracy; A B Newman; W T Ambrosius; M Pahor; S D Anton
Journal:  Ageing Res Rev       Date:  2018-05-25       Impact factor: 10.895

Review 2.  Frailty index as a biomarker of lifespan and healthspan: Focus on pharmacological interventions.

Authors:  Dushani L Palliyaguru; Jacqueline M Moats; Clara Di Germanio; Michel Bernier; Rafael de Cabo
Journal:  Mech Ageing Dev       Date:  2019-03-26       Impact factor: 5.432

Review 3.  Pharmacological targeting of age-related changes in skeletal muscle tissue.

Authors:  Aurel B Leuchtmann; Christoph Handschin
Journal:  Pharmacol Res       Date:  2019-03-04       Impact factor: 7.658

4.  Effect of Losartan and Fish Oil on Plasma IL-6 and Mobility in Older Persons. The ENRGISE Pilot Randomized Clinical Trial.

Authors:  Marco Pahor; Stephen D Anton; Daniel P Beavers; Jane A Cauley; Roger A Fielding; Stephen B Kritchevsky; Christiaan Leeuwenburgh; Kristina H Lewis; Christine K Liu; Laura C Lovato; Jane Lu; Todd M Manini; Mary M McDermott; Michael E Miller; Anne B Newman; Barbara Radziszewska; Cynthia L Stowe; Russell P Tracy; Michael P Walkup; Samuel S Wu; Walter T Ambrosius
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-09-15       Impact factor: 6.053

Review 5.  How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection.

Authors:  Kajetan Kiełbowski; Mariola Herian; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

6.  Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice.

Authors:  Nazaneen Saleh; Caglar Cosarderelioglu; Ramya Vajapey; Jeremy Walston; Peter M Abadir
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-09-01       Impact factor: 6.591

7.  Chronic Treatment With the ACE Inhibitor Enalapril Attenuates the Development of Frailty and Differentially Modifies Pro- and Anti-inflammatory Cytokines in Aging Male and Female C57BL/6 Mice.

Authors:  Kaitlyn Keller; Alice Kane; Stefan Heinze-Milne; Scott A Grandy; Susan E Howlett
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-07-12       Impact factor: 6.053

Review 8.  Animal models of frailty: current applications in clinical research.

Authors:  Alice E Kane; Sarah N Hilmer; John Mach; Sarah J Mitchell; Rafael de Cabo; Susan E Howlett
Journal:  Clin Interv Aging       Date:  2016-10-26       Impact factor: 4.458

9.  miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling.

Authors:  Daijiro Hori; Brittany Dunkerly-Eyring; Yohei Nomura; Debjit Biswas; Jochen Steppan; Jorge Henao-Mejia; Hideo Adachi; Lakshmi Santhanam; Dan E Berkowitz; Charles Steenbergen; Richard A Flavell; Samarjit Das
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

10.  Angiotensin-II-induced Muscle Wasting is Mediated by 25-Hydroxycholesterol via GSK3β Signaling Pathway.

Authors:  Congcong Shen; Jin Zhou; Xiaoxiao Wang; Xi-Yong Yu; Chun Liang; Bin Liu; Xiangbin Pan; Qiong Zhao; Jenny Lee Song; Jiajun Wang; Meiyu Bao; Chaofan Wu; Yangxin Li; Yao-Hua Song
Journal:  EBioMedicine       Date:  2017-01-30       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.